The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

One of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

The Phase 3 ResQ201A-NSCLC study (NCT06745908) aims to confirm the efficacy and safety of combination ANKTIVA plus CPI therapy previously demonstrated in the trial QUILT 3.055 and provide evidence ...

ImmunityBio's Anktiva shows strong data in difficult cancers but hasn't significantly boosted the stock, which remains low at $2.94. The company's financial reliance on founder Dr. Soon-Shiong is ...

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

The U.S. Food and Drug Administration (FDA) approved ANKTIVA with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer ...